Pharmacokinetics of Ritonavir and Delavirdine in Human Immunodeficiency Virus-Infected Patients

To evaluate the pharmacokinetic effect of adding delavirdine mesylate to the antiretroviral regimens of human immunodeficiency virus (HIV)-infected patients stabilized on a full dosage of ritonavir (600 mg every 12 h), 12 HIV-1-infected subjects had delavirdine mesylate (400 mg every 8 h) added to t...

ver descrição completa

Detalhes bibliográficos

Publicado no:	Antimicrob Agents Chemother
Principais autores:	Shelton, Mark J., Hewitt, Ross G., Adams, John, Della-Coletta, Andrew, Cox, Steven, Morse, Gene D.
Formato:	Artigo
Idioma:	Inglês
Publicado em:	American Society for Microbiology (ASM) 2003
Assuntos:	Pharmacology
Acesso em linha:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC153300/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/12709342/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/AAC.47.5.1694-1699.2003
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!